CDC Probe Continues as Cases of Acute Flaccid Myelitis Rise
WEDNESDAY, Nov. 14, 2018 -- Cases of a mysterious polio-like illness continue to mount in the United States, and health officials are scrambling to figure out the cause.
There are now 252 patients under investigation for acute flaccid myelitis (AFM), an increase of 33 patients since last week, said Nancy Messonnier, M.D., director of the National Center for Immunization and Respiratory Diseases at the U.S. Centers for Disease Control and Prevention. CDC researchers have confirmed 90 cases in 27 states, an additional 10 since last week, Messonnier said in a media briefing earlier today. Most patients are children between the ages of 2 and 8 years.
It is possible AFM is caused by a virus. Enteroviruses and rhinoviruses were found in about half of respiratory or stool specimens taken from patients with confirmed cases of AFM, Messonnier said. In addition, researchers found one each of two leading viral suspects -- enteroviruses D68 and A71 -- in spinal fluid samples taken from two patients with confirmed AFM. One patient was an adult on immunosuppressive drugs, and the other was a child who had very rapid progression of paralysis.
"When a pathogen is found in the spinal fluid, it is good evidence that it was the cause of a patient's illness," Messonnier said. But the CDC cannot rule out other infections as potential causes. "It's possible it's a direct effect of one of the viruses that we've already found," Messonnier added. "It's possible it's a virus we haven't found yet. It's also possible the infection is triggering the body's own immune response, and it's actually the immune response that's causing AFM."
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.